ProteoThera, Inc. Receives USPTO Grant of Key Patent Supporting Matrix-Binding Technology Platform

Share Article

ProteoThera, Inc., a biotechnology company with a platform technology for local, targeted drug delivery, announced today that a notice of grant has been received from the US Patent and Trademark Office (USPTO) for a fundamental patent entitled, “Methods of promoting cardiac repair using growth factors fused to heparin binding sequences,” to which ProteoThera has exclusive worldwide rights through its existing agreement with Brigham and Women's Hospital. The newly granted patent (number 9187517) includes composition-of-matter claims covering certain therapeutic uses of insulin-like growth factor 1 (IGF-1) when transformed by fusion with an endogenous matrix-binding targeting sequence.

News Image
This patent is the initial plank in our our proprietary technology platform for changing how drugs are targeted to the tissues where they are needed to be effective and establishes the leadership of ProteoThera in tissue-targeting solutions for proteins.

ProteoThera, Inc., a biotechnology company with a platform technology for local, targeted drug delivery, announced today that a notice of grant has been received from the US Patent and Trademark Office (USPTO) for a fundamental patent entitled, “Methods of promoting cardiac repair using growth factors fused to heparin binding sequences,” to which ProteoThera has exclusive worldwide rights through its existing agreement with Brigham and Women's Hospital. The newly granted patent (number 9187517) includes composition-of-matter claims covering certain therapeutic uses of insulin-like growth factor 1 (IGF-1) when transformed by fusion with an endogenous matrix-binding targeting sequence.

ProteoThera, Inc., a biotechnology company with a platform technology for local, targeted drug delivery, announced today that a notice of grant has been received from the US Patent and Trademark Office (USPTO) for a fundamental patent entitled, “Methods of promoting cardiac repair using growth factors fused to heparin binding sequences,” to which ProteoThera has exclusive worldwide rights through its existing agreement with Brigham and Women's Hospital. The newly granted patent (number 9187517) includes composition-of-matter claims covering certain therapeutic uses of insulin-like growth factor 1 (IGF-1) when transformed by fusion with an endogenous matrix-binding targeting sequence.

“We are very pleased that the USPTO has validated the novelty and innovation of the concept driving our matrix-binding technology platform,” said Dr. Patwari, who is the Chief Scientific Officer at ProteoThera, Inc. “This patent is the initial plank in our proprietary technology platform for changing how drugs are targeted to the tissues where they are needed to be effective and establishes the leadership of ProteoThera in tissue-targeting solutions for proteins.”

This is the first United States patent covering the matrix-binding technology, with multiple subsequent applications in prosecution. In granting the patent, which was applied for on November 7, 2007, the USPTO also awarded a patent term extension of 288 days. Patents based on this application have already been granted by the European Patent Office and the Mexican Institute of Industrial Property. The granted patent includes 19 claims covering the use of the native heparin-binding domain of HB-EGF linked to the growth factor IGF-1 for targeting cartilage tissue in vitro and in vivo. The effectiveness of the strategy disclosed in this patent has also been described in two scientific publications: Tokunou et al., published in the FASEB Journal in 2008, and Miller et al, published in the journal Arthritis and Rheumatism in 2010.

About ProteoThera, Inc.
ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology. The Company's transformative platform technology, a proprietary tissue matrix-binding (MB) peptide technology, is being developed to improve clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.

The MB targeting technology was developed at Brigham and Women’s Hospital and Harvard Medical School. The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally or subcutaneous delivered proteins, peptides, and small molecules. ProteoThera’s focus on previously validated or approved therapies greatly de-risks the clinical, regulatory, and commercial pathways. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patrick ODonnell
Visit website